Medexus Pharmaceuticals Inc's stock surged by 3.33% in the last trading session, reflecting positive investor sentiment.
Medexus Pharmaceuticals Inc (MDP.TO) experienced a notable increase in its stock price, closing at CA$4.34. This rise comes amidst a backdrop of the company's promising fiscal results and strategic developments in its product offerings.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$160.20M
52W high
$5.25
52W low
$2.47
1W change
+2.05%
Beta
1.84
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 36.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.81
+36.7% Upside
Current Price
C$4.98
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
49.8%
Annualized
90-Day Vol
42.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$5.95
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.29 | C$4.45 – C$6.28 |
| 60 trading days | C$5.61 | C$4.40 – C$7.15 |
| 90 trading days | C$5.95 | C$4.42 – C$8.02 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors are responding favorably to Medexus's recent performance metrics and product developments, indicating a potential for continued growth.
Medexus Pharmaceuticals Inc sees a 3.33% rise in stock price.
With a market cap of CA$135.66 million, Medexus is navigating a challenging landscape but shows potential for growth driven by its product pipeline.
Bull case
The company’s strong fiscal year 2026 results and the successful performance of GRAFAPEX (treosulfan) for Injection are boosting investor confidence. This suggests that Medexus may have a solid growth path ahead.
Bear case
Despite the positive movement, investors should stay cautious. The company has a negative profit margin and limited market coverage, which could pose risks.
Strong Fiscal Performance
Advertisement
Medexus recently announced its fiscal year 2026 results, showcasing strong performance metrics that have positively influenced investor sentiment. The successful rollout of GRAFAPEX (treosulfan) for Injection has been a key driver of this momentum, indicating that the company is on a solid growth path.
Strategic Developments
The company has also entered into a license and supply agreement for UM171 Cell Therapy in Canada, which could enhance its product portfolio. This strategic move is likely to attract further interest from investors looking for growth opportunities in the biotech sector.
Market Sentiment and Future Outlook
With a market cap of CA$135.66 million and a recent stock price increase, Medexus is drawing attention from investors. However, the company’s negative profit margin serves as a reminder of the inherent risks in investing in smaller-cap biotech firms. Investors should keep an eye on upcoming developments and earnings calls for further insights.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
